Porton Advanced Cell Gene Therapy CDMO

Porton Advanced Cell Gene Therapy CDMO is a small company based in Cranbury, New Jersey, with 5 employees and annual revenue of $100 million. Porton Advanced specializes in providing comprehensive Cell and Gene Therapy (CGT) services, acting as a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO). They offer a wide range of services to clients at all stages of development, from pre-clinical to commercial, including research, process development, analytical development, GMP manufacturing, and testing. Their expertise spans various CGT platforms such as AAV, Lentivirus, mRNA, and plasmid therapies. The company distinguishes itself through its robust platform-based USP/DSP and GMP manufacturing capabilities, as well as its proprietary technologies designed to support client successes. Porton Advanced's dedicated teams in process and analytical development ensure clients receive high-quality, research-grade services tailored to their specific therapeutic needs. For inquiries and collaboration opportunities, interested parties can reach out via email at [email protected]. More information about Porton Advanced and its services can be found on their website at portonadvanced.com.